Clay Thorp, Director at Clearside Biomedical, Inc. (CLSD), bought 14,000 shares at $1.02 ($14K) on 2022-12-21, disclosed to the SEC on 2022-12-21.
Open-market purchase of $14k CLSD by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| VIGL | BUY | 2022-05-17 | $165K | — | Filing → |
| VIGL | BUY | 2022-03-28 | $22K | — | Filing → |
| VIGL | BUY | 2022-01-11 | $3.7M | — | Filing → |